| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Tregalizumab Basic information |
| Product Name: | Tregalizumab | | Synonyms: | Tregalizumab;Research Grade Tregalizumab;Tregalizumab (anti-CD4) | | CAS: | 1207446-68-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tregalizumab Structure]() |
| | Tregalizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tregalizumab Usage And Synthesis |
| Uses | Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3]. | | References | [1] Knig M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11. DOI:10.3389/fimmu.2016.00011
[2] Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308. DOI:10.1038/srep18308
[3] Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. DOI:10.1038/icb.2014.102 |
| | Tregalizumab Preparation Products And Raw materials |
|